Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VNRX
VNRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNRX News
VolitionRX Reports 133% Revenue Growth in Q4 2025
Apr 03 2026
Yahoo Finance
VolitionRx Q4 2025 Earnings Call Highlights
Apr 01 2026
seekingalpha
VolitionRx Completes Validation of Nu.Q® Vet Cancer Test with Fujifilm
Mar 06 2026
Newsfilter
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
Jan 20 2026
PRnewswire
VolitionRx Makes First Sale of Nu.Q® Cancer Assays to Leading French Cancer Center
Nov 25 2025
Newsfilter
VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Aug 15 2025
Newsfilter
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
Jul 17 2025
Benzinga
Jones Trading Initiates Coverage On VolitionRX with Buy Rating, Announces Price Target of $3
Jun 10 2025
Benzinga
Options Volatility and Implied Earnings Moves Today, May 16, 2025
May 16 2025
TipRanks
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
Mar 20 2025
Newsfilter
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
Jan 08 2025
Benzinga
Volition Issues Business Review 2024
Jan 08 2025
Newsfilter
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Sep 20 2024
Globenewswire
VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024
Aug 14 2024
Business Insider
Here's what Wall Street expects from VolitionRX's earnings
Aug 13 2024
Business Insider
EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
Mar 27 2024
Benzinga
Show More News
